House Bill 1166 revises North Carolina’s Advisory Council on Rare Diseases, also known as Taylor’s Law, by moving the council from the UNC School of Medicine to the Department of Health and Human Services. It updates the council’s membership structure, expands and clarifies appointing authorities, and broadens representation to include clinicians, researchers, patients, caregivers, insurers, Medicaid managed care, industry, genetic counseling, and legislative and executive appointees. The bill also changes administrative support responsibilities to DHHS and keeps the council’s role focused on advising state leaders on rare disease research, diagnosis, treatment, education, and public awareness.
The bill directs the council to continue reporting annually to state officials and legislative oversight bodies, and to work with medical schools, public health schools, hospitals, DHHS, the Drug Utilization Review Board, and the Medicaid Preferred Drug List Review Panel on recommendations for care and treatment. It also appropriates $250,000 in recurring General Fund money beginning in fiscal year 2026-2027 to DHHS to cover the council’s operating expenses. In effect, the bill shifts the council into a DHHS-based structure while providing dedicated ongoing funding for its work.
The overall sentiment reflected in the bill text is supportive of rare disease advocacy and coordination, with the legislation framed as an effort to strengthen the state’s response to rare diseases through broader stakeholder participation and stable funding. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of opposition or debate in the available materials. The bill’s structure suggests an intent to institutionalize the council more firmly within state health policy.
The main points of potential contention are likely to involve the transfer of the council from UNC to DHHS, the expansion of membership to include insurers and industry representatives, and the recurring appropriation of state funds. Those changes could raise questions about administrative control, balance of representation, and ongoing fiscal impact. However, no specific objections are documented in the provided context.
HB1166 amends Chapter 130A of the North Carolina General Statutes to reorganize the Advisory Council on Rare Diseases, moving it from the University of North Carolina at Chapel Hill School of Medicine to the Department of Health and Human Services. It revises the council’s membership, terms, administrative support, chair selection, and duties, and it creates a recurring appropriation of $250,000 from the General Fund to DHHS beginning in fiscal year 2026-2027. The bill affects state health policy coordination, rare disease advocacy, and the agencies and stakeholders involved in advising on diagnosis, treatment, research, and public awareness.
The bill appears generally favorable and policy-driven, with a clear emphasis on improving state coordination and support for people affected by rare diseases. The available record contains no committee transcript or vote data showing opposition, amendment disputes, or divided sentiment. Based on the text alone, the measure seems designed as a constructive reorganization and funding bill rather than a controversial policy change.
Potential contention centers on three issues: the transfer of the council from UNC to DHHS, the inclusion of insurers and biopharmaceutical/industry representatives on the council, and the new recurring state appropriation. Advocates for patient-centered governance may favor the broader council composition and dedicated funding, while others could question whether the membership balance gives too much influence to industry or payers. Administrative and budgetary concerns may also arise from shifting responsibility to DHHS and creating an ongoing General Fund commitment, but no specific objections are documented in the provided materials.